[PDF] Top 20 Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
Has 10000 "Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer" found on our website. Below are the top 20 most common "Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer".
Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer
... solid cancer based on mouse models, clinical re- ports of complete remission in patients are very ...the T cell suppressive microenviron- ment in solid cancers and the large tumor burden in ad- vanced ... See full document
14
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses
... than target antigen loss in meso-CAR T ...get antigen loss and T cell hypofunction or insufficient tumor infiltration are major causes of tumor relapse for adoptive cell therapies ... See full document
18
Chimeric antigen receptor T cells: a novel therapy for solid tumors
... ferentiation antigen, which derived from the 69-KDa precursor protein encoded by Mesothelin gene [81, ...of mesothelin almost re- mains unknown. Some studies suggest that mesothelin is the ... See full document
13
Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
... CAR-T cells can occasionally pose serious or even fatal threats ...engineered T cells retargeting carbonic anhydrase IX (CAIX) in the treatment of metastatic renal cell ...that T ... See full document
10
Cancer biomarkers for targeted therapy
... or cancer biomarkers are major targets for cancer ...the cancer biomarkers include monoclonal antibodies (MoAbs), radiolabeled MoAbs, bispecific T cell engagers, and antibody-drug ... See full document
7
Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
... the target antigen, the modified T cells with the second or third generation CARs usually demonstrate sustained proliferation, enhanced production of cytokines and tumor lytic activity, and ... See full document
7
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
... adoptive T-cell therapy are sev- eral hundred times higher than the baseline level, which typically causes a clinical syndrome including fever, hypotension, and neurological changes, potentially leading to rapid ... See full document
11
Abstract: Despite advances in the understanding of its molecular pathophysiology, prostate cancer
... CAR T cells and demonstrate that CAR therapies represents one of the most effective immune-based treatments of cancer ...safe target antigens) and the largely unsatisfactory results obtained ... See full document
14
Car Drivers and Fuel Sources: How Distinct Signaling Domains in Chimeric Antigen Receptors Reprogram T Cells
... for cancer involves surgical resection, chemotherapy or radiation either alone or in ...surrounding cells and may have little influence on metastasized tumor masses, thereby yielding unsatisfactory ...of ... See full document
134
<p>Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer</p>
... CAR-T cells. Two different kinds of CAR were modi fi ed on T cells to recognize different tumor surface antigen targets, one of which was responsible for the transmission of killing ... See full document
8
T cells expressing chimeric antigen receptor promote immune tolerance
... of T cells to direct their activation to specific targets in vivo has become a success- ful strategy for cancer immunotherapy, but relatively less is known about how adoptive transfer of activated ... See full document
18
Construction and evaluation of a novel humanized HER2 specific chimeric receptor
... human T cells expressing chA21 scFv-28z-based CARs lysed HER2+ breast and ovarian cancer cells with high ...CAR T cells recognized and killed tumor cells in an ... See full document
10
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
... pursued. T cells expressing scFv-based CARs had demonstrated pre- clinical activity against a variety of tumor targets [14 – ...CAR target selected for clinical application was TAG-72, an oncofetal ... See full document
14
T Cells Bearing a Chimeric Antigen Receptor Against the Tumor Vasculature Destroy the Tumor Endothelium and Result in Tumor Regression
... two chimeric antigen receptors (CAR)s against the tumor vasculature, targeting either tumor endothelial marker 1 (TEM1) or prostate-specific membrane antigen ...CAR T cells ... See full document
127
MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells
... of cancer cells (expression confidence > 3) because the cy- tomembrane expression of CTAs is important for the construction of CAR-T cells ... See full document
18
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma
... uses chimeric antigen receptor-modified T cells (CAR-T) or genetically modified NK cells, has been shown to be a promising strategy for the treatment of ...tumor ... See full document
21
Universal CARs, universal T cells, and universal CAR T cells
... approved T cell products with chimeric antigen receptors (CAR) are from autologous T ...CAR T cells approved for clinical use must be generated on a custom-made ...autologous ... See full document
9
Rejection of Experimental Hodgkins Lymphoma by T Cells Engineered with a CD19 Chimeric Antigen Receptor
... L591 cells concurrently with sc or iv inoculation of either 5 × 10 7 CD19-CAR engineered cells or CTL-A cells (an EBV-specific CTL, matching two MHC loci with ...CTL-A cells sc developed ... See full document
9
Gut microbiome and CAR-T therapy
... Novel orally delivered beta-lactamases, intended to degrade β-lactam antibiotics in the upper GI tract to pro- tect the gut microbiome, have shown the ability to limit the emergence of antimicrobial resistance (AMR) and ... See full document
10
Expansion of Gamma Delta T Cells - A Short Review on Bisphosphonate and K562-Based Methods
... Vγ9Vδ2 T cell from the general PBMC population by ZOL and IL-2 as compared to cell ...Vγ9Vδ2 T cell has been well-validated and requires the presence of accessory cells such as monocytes and other ... See full document
7
Related subjects